« Return to News | Drug Sponsors

Eli Lilly maximizes presence on social media

Friday, September 16, 2011 10:41 AM

Last week the company launched a new YouTube channel and tomorrow Lilly will make its official corporate debut on Facebook, according to InPharm.

The company is obviously undeterred by August's Facebook changes, which forced pharma companies to allow their pages to host user comments, something the industry had previously been allowed to block.

More details of Lilly’s Facebook presence will be released at tomorrow’s e-Advocacy Summit, a one-day event the company has organized in collaboration with non-profit advocacy group the Global Healthy Living Foundation.

On YouTube the company has gone for a non-branded approach with its Lilly Health Channel, which focuses on health and wellness, employee and community outreach efforts and health innovation.

“The Lilly Health Channel enables us to tell our unique stories, educate and inspire through video, like we never have before,” the company said.

Lilly launched its Lilly Pad blog, and accompanying Twitter account, last September to give it more of a voice in areas such as public policy, corporate responsibility initiatives, advocacy, and the work of its employees.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.